Skip to main content

The independent medical news service

Breast cancer

26-11-2020 | Oncology | News | Article

ctDNA predicts breast cancer relapse risk

Elevated levels of circulating tumor DNA are associated with significantly worse disease-free survival in patients with early, locally advanced, or metastatic breast cancer, indicates a meta-analysis.

26-11-2020 | Oncology | News | Article

Oligometastatic cancer outcomes acceptable with SABR

Stereotactic ablative radiotherapy is associated with “clinically acceptable” rates of toxicity, local control, progression-free survival, and overall survival in people with oligometastatic cancer, meta-analysis data suggest.

25-11-2020 | Oncology | News | Article

Fertility preservation efficacy demonstrated for breast cancer patients

A nationwide study of Swedish breast cancer patients has demonstrated that receipt of fertility preservation significantly improves reproductive outcomes compared with the absence of such care.

19-11-2020 | Oncology | News | Article

FDA approves pembrolizumab for PD-L1-expressing advanced TNBC

Click here to read more on this announcement

17-11-2020 | Oncology | News | Article

Mammographic breast density adds value to lymphedema prediction

Mammographic breast density is independently associated with lymphedema risk in women who undergo curative surgery for breast cancer and could be added to established risk factors to predict lymphedema severity, say researchers.

13-11-2020 | Oncology | News | Article

Treatment decisions by CTC count may be suitable in metastatic breast cancer

Using circulating tumor cell count to guide first-line treatment decisions in hormone receptor-positive, HER2-negative metastatic breast cancer could be a reliable alternative to a choice based on clinical features, research shows.

10-11-2020 | Oncology | News | Article

Major impact of COVID-19 pandemic on breast cancer care reported

A survey of Italian breast cancer units has highlighted the severe impact of the global SARS-CoV-2 outbreak on the management of individuals with breast cancer.

06-11-2020 | Oncology | News | Article

Oncologic outcomes not affected by immediate postmastectomy reconstruction

Women with breast cancer who undergo immediate breast reconstruction with nipple- or skin-sparing mastectomy after neoadjuvant chemotherapy have similar outcomes to those who receive conventional mastectomy, researchers report.

03-11-2020 | Oncology | News | Article

Novel biomarker of response to neoadjuvant breast cancer chemotherapy identified

The endothelial cell expression of phosphorylated–focal adhesion kinase could serve as a prognostic biomarker in women who receive neoadjuvant chemotherapy for locally advanced breast cancer, research suggests.

29-10-2020 | Oncology | News | Article

Updated estimates of HRT-associated breast cancer risk reported

UK researchers have provided updated estimates of the risks for breast cancer associated with the use of various hormone replacement therapy preparations.

29-10-2020 | Oncology | News | Article

Enzalutamide boosts exemestane efficacy in some HR-positive breast cancer patients

The addition of enzalutamide to exemestane may improve the progression-free survival of a subset of patients with HR-positive, HER2-negative, advanced breast cancer, study data suggest.

28-10-2020 | Oncology | News | Article

Meta-analysis confirms CDK4/6 inhibitor benefit for HR-positive metastatic breast cancer

The addition of CDK4/6 inhibitors to endocrine therapy is associated with improved outcomes in patients with hormone receptor-positive, HER2-negative metastatic breast cancer, shows a meta-analysis.

21-10-2020 | Oncology | News | Article

Gene-based model may identify high-risk breast cancer patients

A prognostic model based on eight DNA repair-related genes may help identify women with breast cancer who are at high risk for death, Chinese researchers report.

16-10-2020 | Oncology | News | Article

High opioid adverse event risk after breast cancer treatment extends beyond misuse

Older women who are prescribed opioids within a year of finishing active treatment for breast cancer have an immediately elevated risk for serious adverse events, including, but not limited to, those associated with opioid misuse, suggests a review of medical records.

15-10-2020 | Oncology | News | Article

No benefit of adding pembrolizumab to eribulin for metastatic breast cancer

The addition of pembrolizumab to eribulin does not improve the survival outcomes of patients with hormone receptor-positive, HER2-negative metastatic breast cancer, suggests a phase 2 study.

13-10-2020 | Oncology | News | Article

Sacituzumab govitecan shows promise for HR+, HER2– metastatic breast cancer

Early data suggest almost a third of patients with metastatic breast cancer could benefit from treatment with the Trop-2-directed antibody–drug conjugate sacituzumab govitecan.

06-10-2020 | Oncology | News | Article

pCR predicts 5-year survival for early-stage, HR-positive, HER2-positive breast cancer

Pathologic complete response is significantly associated with 5-year survival outcomes for early-stage breast cancer patients with hormone receptor-positive, HER2-positive disease, shows research reported at the ESMO Virtual Congress 2020.

02-10-2020 | Oncology | News | Article

PALLAS: No reduction in relapse risk with adjuvant palbociclib in early breast cancer

The addition of palbociclib to adjuvant endocrine therapy does not prolong invasive disease-free survival in hormone receptor-positive, HER2-negative, stage II–III breast cancer, shows the phase 3 PALLAS trial.

28-09-2020 | Oncology | News | Article

Neoadjuvant atezolizumab–chemotherapy improves TNBC pathologic response

Combining atezolizumab with standard neoadjuvant chemotherapy achieves significantly higher pathologic complete response rates than chemotherapy alone in individuals with stage II–III triple-negative breast cancer, indicates the IMpassion031 trial.

24-09-2020 | Oncology | News | Article

FLIPPER: Postmenopausal breast cancer patients benefit from first-line palbociclib–fulvestrant

Adding palbociclib to fulvestrant as first-line therapy improves 1-year progression-free survival in postmenopausal women with hormone receptor-positive, HER2-negative, endocrine-sensitive, metastatic breast cancer, shows the phase 2 FLIPPER trial.

Image Credits